News items related to: Call to action
-
Activists Demand $40-a-year Generic Price for Breakthrough HIV Prevention Drug be Made Available to all Low- and Middle-Income Countries
A global coalition reacted to two deals announced today to make long acting lenacapavir (LEN-LA), a 6 monthly HIV PrEP...
-
UN High-Level Meeting on NCDs: Declaration Without Affordability Is Just Empty Words
Weaknesses in the Draft Declaration Civil society groups warn that the latest draft does not reference the right of governments...
-
An Earsplitting Silence: Pharma Makes Billions, Says Nothing About the Current Global Funding Crisis for HIV, Tuberculosis and Other Life-Threatening Illnesses
“It is shocking that the crisis facing the global HIV community has been met with such a resounding silence from...
-
10th December Human Rights Day 2024: Achieving Equity in HIV Treatment and Prevention
On this Human Rights Day, the Global Network of People Living with HIV (GNP+) and the International Treatment Preparedness Coalition...
-
Why the World Can’t Trust Pharmaceutical Companies to Ensure Global Access to Essential Medicines
ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV...
-
HIV Community-Based Organizations are Fighting Patent Monopolies on Lenacapavir
Despite the world’s efforts, there have been over a million new cases of HIV each year. Lenacapavir (LEN), a long-acting...
-
ITPC Sounds Alarm to Prevent Mpox Treatment Disparities as WHO Declares Global Health Emergency
July 15, 2024 — ITPC Global welcomes the World Health Organization’s (WHO) declaration of the current mpox upsurge as a Public...
-
Activists at AIDS2024 called on ViiV Healthcare to drop their case in Colombia against Compulsory License on Dolutegravir
On the 24th of July, hundreds of treatment advocates attending AIDS2024 in Munich protested against the companies with “Drop The...
-
People’s Resolution: A Roadmap to Protect the Right to Life in a Failed Multilateral Order
We, as members of communities, civil society and activists affected by epidemics, call for a plan of action to end...
-
J & J’s Deal With the Global Drug Facility Disguises the Continued Issue with Access to Bedaquiline to Treat Drug-Resistant Tuberculosis
“This deal is big step backwards for global public health – it allows J & J to keep selling higher-priced...
-
Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline
July 1, 2022 – A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global...
-
COVID-19 Pandemic: Bolsonaro and the Pharmaceutical Industry Are United Against Access to Medicines in Brazil
A new chapter of Bolsonaro’s deliberate strategy to spread the coronavirus has begun. This time, his government is partnering with...